Better PET Imaging Predicts Who Will Respond to Peptide Cancer Therapy

A multivariate linear regression model using comprehensive, lesion-level, longitudinal features from Ga-68 DOTA-TATE PET scans achieved a concordance index of 0.826, AUC of 0.88 (85% specificity, 81% sensitivity), and significant patient stratification into good and poor responders (PFS ≥25 months cutoff, p < 0.00001). This approach outperformed all single-feature predictors in a benchmark study.

Retrospective study of 36 NET patients treated with 177Lu-DOTA-TATE and imaged with 68Ga-DOTA-TATE PET at baseline and post-therapy. All individual lesions were segmented, anatomically labeled, and longitudinally matched between scans. Patient-level features were engineered from lesion-level data and selected for multivariate modeling. Validated via concordance index, ROC analysis, and Kaplan-Meier survival analysis.

PRRT is expensive and not all patients respond equally. Being able to predict who will benefit — with 88% accuracy — could prevent unnecessary treatment for likely non-responders and fast-track therapy for likely responders. It also demonstrates the power of comprehensive peptide-receptor imaging analysis.

This represents the 'precision' in precision medicine for peptide-targeted therapy: using the very same somatostatin receptor imaging that selects patients for treatment to also predict how well they'll respond. Better prediction models help allocate this specialized therapy to those most likely to benefit.

Small cohort of only 36 patients — needs external validation in larger populations. Retrospective design. Comprehensive lesion segmentation is labor-intensive and not yet automated. Model performance may not generalize across different institutions or scanner types.